Truist Securities has upgraded Lantheus Holdings Inc (LNTH) from Hold to Buy, signaling a more optimistic outlook on the company's future. This change, effective December 11, 2025, comes as Lantheus continues to navigate the health care landscape with its range of diagnostic imaging and nuclear medicine products.
Headquartered in North Billerica, Massachusetts, Lantheus specializes in radiopharmaceutical oncology, precision diagnostics, and strategic partnerships. The company employs 808 full-time staff and has a market capitalization of $3.5 billion. With a price-to-earnings ratio of 12.91 and earnings per share of 3.76, Lantheus is positioned to capitalize on its offerings, which include products like PYLARIFY and DEFINITY.
Upcoming earnings reports are on the horizon, with estimates suggesting an EPS of $1.30 and revenue of $376.2 million for August 4, 2026. Recent performance has shown mixed results, including a Q3 2025 EPS of $1.27, slightly below expectations, but the overall sentiment appears to be shifting positively.
Analyst ratings serve as a professional assessment based on financial models and research, and they can provide valuable insights. However, these ratings reflect assumptions that may not always align with future performance. Investors are encouraged to consider a range of factors, including company fundamentals and market trends, when making decisions. Analyst opinions can evolve as new information emerges, and differing viewpoints may exist within the analyst community.